Misonix, Inc. to Report Fourth Quarter and Fiscal Year 2012 Financial Results on
Tuesday, September 18, 2012
Conference call to be conducted at 4:30 pm ET
FARMINGDALE, N.Y., Sept. 12, 2012 /PRNewswire via COMTEX/ -- Misonix, Inc.
(MSON), a surgical device company that designs, manufactures and markets
innovative therapeutic ultrasonic products worldwide for wound debridement,
spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery and other
surgical applications, announced today that it will report financial results for
the fourth quarter and fiscal year ended June 30, 2012 on Tuesday, September 18,
2012. The Company has scheduled a conference call that same day, Tuesday,
September 18, 2012, at 4:30 pm ET to review the results.
Interested parties can access the conference call by dialing (877) 317-6789 or
(412) 317-6789 or can listen via a live Internet webcast, which is available in
the Investor Relations section of the Company's website at
misonix.com.
A teleconference replay of the call will be available for three days at (877)
344-7529 or (412) 317-0088, confirmation # 10018380. A webcast replay will be
available in the Investor Relations section of the Company's website at
misonix.com for 30 days.
About Misonix, Inc. Misonix, Inc. designs, develops, manufactures and markets
therapeutic ultrasonic surgical devices. Misonix's therapeutic ultrasonic
platform is the basis for several innovative medical technologies. Addressing a
combined market estimated to be in excess of $3 billion annually, Misonix's
proprietary ultrasonic medical devices are used for wound debridement, cosmetic
surgery, neurosurgery, laparoscopic surgery, and other surgical and medical
applications. Additional information is available on the Company's Web site at
misonix.com.
Safe Harbor Statement With the exception of historical information contained in
this press release, content herein may contain "forward looking statements" that
are made pursuant to the Safe Harbor Provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based on management's current
expectations and are subject to uncertainty and changes in circumstances.
Investors are cautioned that forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially from the
statements made. These factors include general economic conditions, delays and
risks associated with the performance of contracts, risks associated with
international sales and currency fluctuations, uncertainties as a result of
research and development, acceptable results from clinical studies, including
publication of results and patient/procedure data with varying levels of
statistical relevancy, risks involved in introducing and marketing new products,
potential acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such activities,
the timing of finding strategic partners and implementing such relationships,
regulatory risks including approval of pending and/or contemplated 510(k)
filings, the ability to achieve and maintain profitability in the Company's
business lines, and other factors discussed in the Company's Annual Report on
Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form
8-K. The Company disclaims any obligation to update its forward-looking
relationships.
Company Contact:Investor Contacts:
Richard ZarembaRobert Blum, Joe Dorame, Joe Diaz
Misonix, Inc.Lytham Partners, LLC
631-694-9555602-889-9700
invest@misonix.com mson@lythampartners.com
misonix.comhttp://www.lythampartners.com |
